ZA977326B - Tetrahydroquinoline derivatives - Google Patents

Tetrahydroquinoline derivatives

Info

Publication number
ZA977326B
ZA977326B ZA977326A ZA977326A ZA977326B ZA 977326 B ZA977326 B ZA 977326B ZA 977326 A ZA977326 A ZA 977326A ZA 977326 A ZA977326 A ZA 977326A ZA 977326 B ZA977326 B ZA 977326B
Authority
ZA
South Africa
Prior art keywords
tetrahydroquinoline derivatives
tetrahydroquinoline
derivatives
Prior art date
Application number
ZA977326A
Other languages
English (en)
Inventor
Romano Di-Fabio
Alessandra Pasquarello
Fabio Maria Sabbatini
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Publication of ZA977326B publication Critical patent/ZA977326B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
ZA977326A 1996-08-17 1997-08-14 Tetrahydroquinoline derivatives ZA977326B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9617305.9A GB9617305D0 (en) 1996-08-17 1996-08-17 Heterocyclic compounds

Publications (1)

Publication Number Publication Date
ZA977326B true ZA977326B (en) 1999-02-15

Family

ID=10798623

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA977326A ZA977326B (en) 1996-08-17 1997-08-14 Tetrahydroquinoline derivatives

Country Status (34)

Country Link
US (1) US6479488B1 (cs)
EP (1) EP0922034B1 (cs)
JP (1) JP4108129B2 (cs)
KR (1) KR100552864B1 (cs)
CN (1) CN1131214C (cs)
AP (1) AP877A (cs)
AR (1) AR008296A1 (cs)
AT (1) ATE221052T1 (cs)
AU (1) AU724473B2 (cs)
BR (1) BR9711311B1 (cs)
CA (1) CA2264118C (cs)
CO (1) CO4900066A1 (cs)
CZ (1) CZ296250B6 (cs)
DE (1) DE69714265T2 (cs)
DK (1) DK0922034T3 (cs)
EA (1) EA001704B1 (cs)
ES (1) ES2181030T3 (cs)
GB (1) GB9617305D0 (cs)
HU (1) HU225797B1 (cs)
ID (1) ID18095A (cs)
IL (1) IL128141A0 (cs)
IS (1) IS4953A (cs)
MY (1) MY116952A (cs)
NO (1) NO312241B1 (cs)
NZ (1) NZ333812A (cs)
PE (1) PE107098A1 (cs)
PL (1) PL194532B1 (cs)
PT (1) PT922034E (cs)
SI (1) SI0922034T1 (cs)
TR (1) TR199900336T2 (cs)
TW (1) TW449582B (cs)
WO (1) WO1998007704A1 (cs)
YU (1) YU6799A (cs)
ZA (1) ZA977326B (cs)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706294D0 (en) * 1997-03-26 1997-05-14 Glaxo Wellcome Spa Heterocyclic compound
MY125037A (en) 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
GB9929037D0 (en) * 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
DE10132725A1 (de) 2001-07-05 2006-08-03 Grünenthal GmbH Substituierte γ-Lactonverbindungen
JP4509565B2 (ja) * 2001-12-28 2010-07-21 アカディア ファーマシューティカルズ,インコーポレーテッド ムスカリン作動薬としてのテトラヒドロキノリン類似体
US20050085463A1 (en) * 2003-01-23 2005-04-21 Weiner David M. Use of N-desmethylclozapine to treat human neuropsychiatric disease
US20050250767A1 (en) * 2003-01-23 2005-11-10 Weiner David M Use of N-desmethylclozapine to treat human neuropsychiatric disease
EP1994932A1 (en) * 2003-01-23 2008-11-26 Arcadia Pharmaceuticals Inc. Use of N-desmethylclozapine to treat human psychosis
EP1596867A4 (en) * 2003-02-19 2006-03-22 Merck & Co Inc TREATMENT OF PSYCHOSIS WITH A MUSCARIN M1 RECEPTOR ECTOPIC ACTIVATOR
WO2005063254A2 (en) * 2003-12-22 2005-07-14 Acadia Pharmaceuticals Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20050282800A1 (en) * 2004-04-01 2005-12-22 Bo-Ragnar Tolf Method of synthesis and isolation of solid N-desmethylclozapine and crystalline forms thereof
US7910751B2 (en) * 2005-07-22 2011-03-22 Mochida Pharmaceutical Co., Ltd. Heterocyclidene acetamide derivative
RU2451014C2 (ru) * 2005-07-22 2012-05-20 Мотида Фармасьютикал Ко., Лтд. Новое производное гетероциклиден ацетамида
US9427419B2 (en) 2005-09-12 2016-08-30 Abela Pharmaceuticals, Inc. Compositions comprising dimethyl sulfoxide (DMSO)
US8480797B2 (en) 2005-09-12 2013-07-09 Abela Pharmaceuticals, Inc. Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors
WO2007033180A1 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds
US7955418B2 (en) 2005-09-12 2011-06-07 Abela Pharmaceuticals, Inc. Systems for removing dimethyl sulfoxide (DMSO) or related compounds or odors associated with same
WO2007053618A1 (en) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
BRPI0921494A2 (pt) 2008-11-03 2018-10-30 Prad Reasearch And Development Ltd método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração.
MX353712B (es) 2009-10-30 2018-01-24 Abela Pharmaceuticals Inc Formulaciones de sulfoxido de dimetilo (dmso) y metilsulfonilmetano (msm) para tratar osteoartritis.
WO2013055386A2 (en) 2011-10-03 2013-04-18 The University Of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL93610A0 (en) * 1989-03-08 1990-12-23 Merck Sharp & Dohme Tetrahydroquinoline derivatives,their preparation and pharmaceutical compositions containing them
EP0854867B1 (en) * 1995-09-29 2002-07-31 GLAXO WELLCOME S.p.A. Tetrahydroquinolines as nmda antagonists

Also Published As

Publication number Publication date
CZ52999A3 (cs) 1999-07-14
KR100552864B1 (ko) 2006-02-20
NO990723L (no) 1999-04-14
YU6799A (sh) 2000-03-21
IL128141A0 (en) 1999-11-30
EA001704B1 (ru) 2001-06-25
KR20000068172A (ko) 2000-11-25
ATE221052T1 (de) 2002-08-15
TW449582B (en) 2001-08-11
HUP9903108A3 (en) 2004-04-28
EP0922034B1 (en) 2002-07-24
PT922034E (pt) 2002-12-31
AP9901459A0 (en) 1999-03-31
DK0922034T3 (da) 2002-11-18
NZ333812A (en) 2000-07-28
AU4551897A (en) 1998-03-06
NO312241B1 (no) 2002-04-15
AR008296A1 (es) 1999-12-29
CA2264118C (en) 2008-06-17
TR199900336T2 (xx) 1999-04-21
SI0922034T1 (en) 2003-02-28
CZ296250B6 (cs) 2006-02-15
HU225797B1 (en) 2007-09-28
PL194532B1 (pl) 2007-06-29
CO4900066A1 (es) 2000-03-27
BR9711311A (pt) 1999-08-17
WO1998007704A1 (en) 1998-02-26
ID18095A (id) 1998-02-26
JP4108129B2 (ja) 2008-06-25
CA2264118A1 (en) 1998-02-26
NO990723D0 (no) 1999-02-16
IS4953A (is) 1999-01-22
EA199900121A1 (ru) 1999-10-28
CN1227544A (zh) 1999-09-01
US6479488B1 (en) 2002-11-12
PL331562A1 (en) 1999-07-19
AU724473B2 (en) 2000-09-21
PE107098A1 (es) 1999-01-15
MY116952A (en) 2004-04-30
GB9617305D0 (en) 1996-09-25
DE69714265T2 (de) 2003-03-06
AP877A (en) 2000-09-27
ES2181030T3 (es) 2003-02-16
BR9711311B1 (pt) 2009-01-13
EP0922034A1 (en) 1999-06-16
JP2001508031A (ja) 2001-06-19
CN1131214C (zh) 2003-12-17
DE69714265D1 (de) 2002-08-29

Similar Documents

Publication Publication Date Title
AP9500745A0 (en) Quinoline derivatives
AP9700954A0 (en) 6-ohenylpyridyl-2-amine derivatives
AP9701156A0 (en) 6-phenylpyridyl-2-amine derivatives
IL125379A (en) 19-nor-pregnene derivatives
ZA977326B (en) Tetrahydroquinoline derivatives
HUP9902993A3 (en) Alkylaminobenzothiazole and -benzoxazole derivatives
HUP9701835A3 (en) Vinyl-pirrolidinone-cephalosporin derivatives
IL129418A0 (en) 2-Methoxyphenylpiperazine derivatives
GB9404378D0 (en) Quinoline derivatives
IL125149A0 (en) Pyrazol-4-yl-hetaroyl derivatives
ZA954269B (en) Quinoline derivatives
HU9701479D0 (en) N-benzylazolium derivatives
PL334558A1 (en) Cephalosporinic derivatives
GB9413150D0 (en) Quinoline derivatives
GB9402275D0 (en) Quinoline derivatives
ZA972051B (en) Benzodiazonine derivatives
GB9603226D0 (en) Heterocyclyl-ergoline derivatives
GB9600063D0 (en) Guaridine derivatives
IL125974A0 (en) 2-thioxotetrahydropyrimidin-4-one derivatives
IL130283A0 (en) Polysaccharide-peptide derivatives
GB9702049D0 (en) Tetrahhydroisoquinoline derivatives
HU9601036D0 (en) Aryl-sulfonyl-hydroxamic-acid derivatives
GB9402306D0 (en) Quinoline derivatives
IL139301A0 (en) Quinoline derivatives
GB9413937D0 (en) Quinoline derivatives